# Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits

Study · id `cardio:ct-nct07944261` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07944261](<https://clinicaltrials.gov/study/NCT07944261>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07944261

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1324 participants.

## Technical summary

Registry record NCT07944261. Randomized; single masking; primary purpose treatment. Start 2026-10-15 (actual); primary completion 2029-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1324 participants (planned count; ClinicalTrials.gov record NCT07944261, source copy `cardio:ctgov-nct07944261-2026-11-18`, retrieved 2026-11-18)
- Started: 2026-10-15 (actual) (ClinicalTrials.gov record NCT07944261, source copy `cardio:ctgov-nct07944261-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2029-04 (anticipated) (ClinicalTrials.gov record NCT07944261, source copy `cardio:ctgov-nct07944261-2026-11-18`, retrieved 2026-11-18)
- Completion: 2029-07 (anticipated) (ClinicalTrials.gov record NCT07944261, source copy `cardio:ctgov-nct07944261-2026-11-18`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07944261, source copy `cardio:ctgov-nct07944261-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07944261-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits
- Acronym: MILD-EFFECT
- Condition: Acute Ischemic Stroke
- Condition: Minor Ischemic Stroke
- Intervention (Drug): Tenecteplase 0.18 mg/kg
- Intervention (Drug): Tenecteplase 0.25 mg/kg
- Lead sponsor: Shandong Provincial Hospital
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Tenecteplase (`cardio:tenecteplase`)
- Registry intervention is a member of this class by a sourced record link: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- Registry lists this organization as the lead sponsor: Shandong Provincial Hospital (`cardio:org-shandong-provincial-hospital`)

## Provenance

Content hash: a07a0ac47b4722f52a5bb80de48f1ea78c95c70c2aa4cf4709192772eaa17a51
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
